Introduction
A major challenge in nanomedicine for cancer diagnosis and therapy is the delivery of imaging agents or anticancer drugs specically and efficiently. [1] [2] [3] [4] [5] To achieve this goal, the use of targeting or recognition motifs for active targeting is considered one of the most promising approaches. 6, 7 Small molecules, targeting peptides, as well as antibodies have been widely reported as targeting agents. [8] [9] [10] However, when incorporated with nanomaterials, the properties of the resulting constructs are oen dictated more by the material used rather than the targeting agent, 11, 12 and consequently developing targeted nanomedicines capable of potential clinical use is still challenging.
13,14
To meet these challenges, DNA aptamers have been investigated as a new class of targeting agent. [15] [16] [17] Aptamers are single-stranded oligonucleotides that can bind to target molecules with excellent specicity and affinity.
18-22
In comparison to antibodies, which suffer from problems with instability and immunogenicity, DNA aptamers are stable in harsh environments and have been demonstrated to be nonimmunogenic. 23 They are easier to prepare and to conjugate to nanomedicine-based platforms. 24, 25 In addition, the targeting functionality of DNA aptamers can be inhibited by complementary DNA sequences, which can thus function as a specic antidote to prevent overdosage in drug delivery. 26 Moreover, in comparison with various previously reported RNA aptamers, DNA aptamers showed reduced susceptibility to biodegradation, which makes them more favorable for clinical applications.
Liposomes are one of the most successful nanomedicine delivery platforms, and have been used to deliver a wide variety of small molecules, genes, imaging agents, and even nanoparticles. 27, 28 Compared with other delivery systems, liposomes offer superior biocompatibility, biodegradability, reduced toxicity and improved control over size and surface functionality. 29 Since liposomes have previously been approved by the United States Food and Drug Administration (FDA) for a number of clinical therapies, starting from this scaffold and incorporating DNA aptamers to incorporate targeting functionality should potentially facilitate the translation to clinical practice. Despite this promise, few studies of DNA aptamernanomedicine constructs have shown successful efficacy in vivo, even though the use of DNA aptamers for targeted drug delivery in vitro has been reported. 26 Demonstrating the efficacy both in vitro and in vivo is important to advance nanomedicine.
In order to investigate this issue, we prepared a nanoscale liposome modied with a 26-mer guanosine-rich DNA aptamer AS1411. AS141 has strong binding affinity to nucleolin (NCL), a bcl2 mRNA-stabilizing protein overexpressed on the plasma membrane of many types of cancer cells, including leukemia and breast cancers. [30] [31] [32] [33] AS1411 has been shown to be remarkably stable against nuclease degradation in serum, which is attributed to the formation of the G-quartet structure. 34 Further pharmacokinetic studies have shown enhanced stability of AS1411 in blood in vivo, which overcomes one of the major limitations reported for potential aptamer use in clinical practice. 35 In previous work, we have demonstrated that the AS1411 DNA aptamer (Apt) facilitated the cellular uptake of cisplatincontaining liposomes and showed higher cytotoxicity to MCF-7 cells than the same liposome system without the aptamer or with a non-aptameric DNA strand (Ctrl). 26 While these in vitro results are promising, it is important to demonstrate the efficacy of the approach in vivo for future clinical applications.
In this study, we report the preparation of AS1411 aptamerfunctionalized liposomes containing an anticancer drug, doxorubicin (Dox). The targeted liposomal doxorubicin (AptDox-Lip) showed selective internalization and enhanced cytotoxicity to MCF-7 breast cancer cells. Athymic nude mice bearing xenogra MCF-7 tumors treated with intratumorally injected Apt-Dox-Lip exhibited an earlier onset of tumor inhibition and improved anticancer efficacy when compared with non-aptameric DNA modied congeners, which is attributable to enhanced tumor penetration and cellular internalization.
Results and discussion
Preparation and characterization of DNA-functionalized liposomes Fig. 1 illustrates the basic design and formulation of aptamerfunctionalized liposomes containing different cargos. The sequence of the NCL aptamer used is 5 0 -GGT GGT GGT GGT TGT GGT GGT GGT GGT TTT TTT TTT TT-Cholesterol-3 0 . The poly-T region in the above sequence serves as a spacer to separate the aptamer recognition sequence from the hydrophobic cholesterol end. A non-aptameric DNA sequence 5 0 -GAG AAC CTG AGT CAG TAT TGC GGA GAT TTT TTT TTT TTCholesterol-3 0 was used as a control. Doxorubicin hydrochloride was chosen as the anticancer agent. Aiming at potential clinical applications of DNA aptamer-modied liposomes, a wellestablished liposome formulation was used as model system for DNA aptamer modication. The liposomes were formulated from HSPC, cholesterol, and mPEG2000-DSPE at a molar ratio of 2 : 1 : 0.16. 36 The aptamer-modied liposome based on this formulation structurally resembles DoxilÒ, an FDA-approved, doxorubicin-containing liposome, except that the latter has no targeting ligand incorporated. 37 This HSPC/Cholesterol/DSPE-PEG formulation has been intensively studied for many years and was reported to be effective for in vivo applications. The combination of HSPC and DSPE possesses a relatively high transition temperature at 48 C, providing liposomes with high rigidity and low permeability at 37 C. 36 Free cholesterol molecules serve as hydrophobic anchors to increase the hydrophobic-hydrophobic interactions in lipids bilayer as well as the rigidity and stability of liposomes. 36 The inert, hydrophilic PEG modication reduces the nonspecic uptake of liposomes.
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The formulation of liposomes provides an excellent system with long-term stability suitable for the in vivo study of aptamerdirected targeted drug delivery. The NCL aptamer-functionalized liposomes of $200 nm in diameter were prepared according to a previously published protocol, using polycarbonate membrane supported extruders. 26 In a typical experiment, the overall lipid concentration was controlled at $8 mg mL À1 in the presence of 12 mM cholesterol-DNA in a preparation buffer (pH 7.4) containing 25 mM HEPES, 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , and 1 mM CaCl 2 . The prepared Dox-containing Apt-liposomes can be easily concentrated via centrifugation (Fig. S2a †) . Under a uorescence microscope, a solution of dye-containing liposomes was observed as separate bright dots, conrming the formation of lipid vesicles (Fig. S2b †) . To further elucidate the structure and morphology of aptamer-modied liposomes, Cryo-EM experiments were performed. As shown in Fig. 2a , the liposomes appeared spherical with a lipid bilayer membrane thickness of several nanometers. The average size is around $200 nm, which agrees well with the pore size of the polycarbonate membrane used in preparation.
To demonstrate the functionalization of liposomes with the DNA aptamer and to achieve a quantitative measure of the DNA density on each liposome, we used a commercially available green-uorescent stain, OliGreenÒ ssDNA reagent, to measure the DNA concentration. Prior to the staining process, Triton-X and heat treatment (80 C) was used to break the lipid vesicles and release DNA strands. The ruptured liposome samples were incubated with the OliGreenÒ reagent for 10 min and excited at 480 nm. As shown in Fig. 2b , liposomes without the DNA aptamer functionalization showed only a low level of background uorescence. Aer attachment of DNA aptamer, Apt-Lip and Ctrl-Lip samples exhibited a strong uorescence emission peak at 520 nm aer staining, demonstrating the presence of ssDNA. Quantitative measurement of DNA concentration in the liposome samples was achieved using a calibration curve generated from a series of standard DNA solutions (Fig. S1 †) . The DNA aptamer concentration of Apt-Lip sample was calculated to be 9.7 mM, with a corresponding conjugation efficiency of $34.6%. The DNA density per liposome was estimated to be $1.1 nmol DNA adsorbed on 1.0 mg of lipids. The DNA-functionalized liposomes were further characterized by Dynamic Light Scattering (DLS) and x-potential measurements. Liposomes without the DNA aptamer functionalization showed an average hydrodynamic diameter of 190 AE 16 nm, which is consistent with the Cryo-EM images. Aer DNA functionalization, an average hydrodynamic diameter of 210 AE 20 nm was observed for both aptamer and control DNA-modied liposomes (Fig. 2c) . In order to further understand the effect of DNA modication on the surface of liposomes, we measured the x-potential of different liposome samples. In a 5 mM HEPES buffer (pH 7.4) containing 10 mM NaCl, liposomes without the DNA aptamer functionalization displayed a x-potential of À4 AE 2 mV, which is consistent with previously reported values for liposomes with this composition. 25 Aer conjugation with the DNA strands, the x-potential of control and aptamer DNA-modied liposome samples decreased to approximately À15 AE 5 mV, further indicating the attachment of negatively charged DNA strands on the surface of the liposomes (Fig. 2d) .
Since the in vivo biological microenvironment is signicantly different from the liposome preparation buffer, it is critical to evaluate the stability of the liposomes under physiological conditions before proceeding to cellular and animal studies. In order to evaluate the stability of the DNA-modied liposomes, we monitored the uorescence intensity of NCL aptamermodied, uranin-containing liposome samples (Apt-Urn-Lip) aer incubation at 37 C in 50% human serum over a period of 24 hours (Fig. 3a) . Fully ruptured Apt-Urn-Lip samples were used as positive control group to illustrate the uorescent intensity aer complete release of uranin (black line). As shown in Fig. 3b , aer 24 hours at 37 C in 50% human serum, less than $10% of the maximum possible enhancement of uo-rescence intensity was observed, suggesting only minimal decomposition of the liposome samples and minimal leakage of encapsulated uranin. Similar release prole was observed for doxorubicin-loaded liposome samples (Fig. S3 †) . These results indicate that the aptamer modied liposome samples are highly stable in 50% human serum with well-preserved uorescent properties. Towards the goal of achieving an enhanced anticancer therapy in vivo, it is also critical to control the drug loading in order to provide sufficient anticancer agent in the aptamerliposome system. The DNA-lipid mixture was incubated with $25 mg mL À1 Dox solution to achieve high Dox loading. The uorescence of the DNA-Dox-Lip sample was measured by excitation at 480 nm before and aer heat treatment (Fig. S4a †) . According to a standard curve of free doxorubicin, the equivalent Dox concentration of a typical Apt-Dox-Lip sample was calculated to be 0.92 mg mL À1 based on uorescence emission intensity of fully decomposed liposomes at 592 nm ( Fig. S4b and S4c †). The drug-to-lipid ratio of the Apt-Dox-Lip sample was estimated to be 0.097 (w/w), which is comparable to the 0.125 (w/w) drug-to-lipid ratio of DoxilÒ, 39 suggesting a sufficient drug loading capacity for in vivo study.
In vitro targeting capability of aptamer-functionalized liposomes
To assess the targeting capability of aptamer-functionalized liposomes, uranin-loaded liposomes that were modied with control DNA (Ctrl-Urn-Lip, 50 mM lipid equivalent) or NCL-Apt (Apt-Urn-Lip, 50 mM lipid equivalent) were incubated with MCF-7 cells separately, and the uorescence of the treated cells was analyzed by ow cytometry (Fig. 4a and Table S1 †). In order to compare their binding affinity with MCF-7 cells, a low sample concentration (50 mM lipid equivalent) and a 4 h incubation time was used. The results showed a 6.6-fold increase in mean uorescence intensity in MCF-7 cells treated with Apt-Urn-Lip versus those treated with Ctrl-Urn-Lip (Table S1 †). It is also noticeable that 93.6% of cells incubated with Apt-Urn-Lip for 4 hours showed a uorescent response, compared to 57.0% for Ctrl-Urn-Lip (Table S1 †) . When the concentration of Urn-Lip was increased to 500 mM, a similar trend was also observed (Fig. S5 †) . The results clearly demonstrated the enhanced binding of Apt-Urn-Lip to the MCF-7 cells compared with Ctrl-Urn-Lip, presumably due to the selective affinity between the NCL aptamer and the nucleolin which was overexpressed on the plasma membrane of MCF-7 cells.
We next investigated whether the increased binding of AptUrn-Lip to MCF-7 cells indeed resulted in enhanced cellular uptake of liposomes by MCF-7 cells. Using confocal uores-cence microscopy with ne z-axis resolution, we studied the localization of Urn-Lip in the treated cells (Fig. 4b) . The nuclei of MCF-7 cells were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI, shown as blue in Fig. 4b ), and the liposomes were labeled with uranin (shown as green in Fig. 4b ). In order to better demonstrate the specicity between targeted (MCF-7) and nontargeted cells (LNCaP), a higher sample concentration (500 mM lipid equivalent) was used. To avoid saturation of uorescent signal in MCF-7 cells under such as a high concentration, cells were incubated for a shorter time (2 h). More green uorescence was observed in the cytoplasm of the MCF-7 cells treated with Apt-Urn-Lip than Ctrl-Urn-Lip, demonstrating that Apt-Urn-Lip was more efficiently internalized by MCF-7 cells. Furthermore, Apt-Urn-Lip was specically internalized by cells which overexpress NCL on the cell membrane, i.e. MCF-7 cells (NCL(+)), but not by LNCaP cells (NCL(À)) (Fig. S6 †) . Together, these results showed that the NCL aptamer-modied liposomes targeted MCF-7 cells selectively and efficiently due to the specic binding of the aptamer to NCL overexpressed on cell membrane.
To evaluate whether the NCL aptamer-functionalized, Doxcontaining liposomes can increase the toxicity of the drug to the cancer cells, we further investigated the cytotoxicity of doxorubicin-loaded, PEGylated liposomes, modied either with NCL aptamer (Apt-Dox-Lip) or a control DNA sequence (CtrlDox-Lip). In order to give MCF-7 cells sufficient time to take up enough liposomes or drugs to compare the cytotoxicity aer another 3 days, cells were incubated with Dox, Ctrl-Dox-Lip or Apt-Dox-Lip samples for 6 h. The cells were further cultured in fresh medium for a total of 72 h before the assessment of cell viability by MTT assay. The results suggested that Apt-Dox-Lip showed signicantly higher cytotoxicity to MCF-7 cells as compared to Ctrl-Dox-Lip (p < 0.01). As shown in Fig. 4c , the cell viabilities were 57.0 AE 6%, 75.0 AE 4%, and 80.9 AE 4% (mean AE SD) for MCF-7 cells treated with Apt-Dox-Lip at equivalent Dox concentration of 500 nM, 100 nM and 10 nM, respectively. In contrast, the cell viabilities were 92.4 AE 9%, 107.2 AE 7%, and 109.7 AE 13% for cells treated with Ctrl-Dox-Lip at the same concentrations, respectively. There was no statistical signi-cance when comparing the cytotoxicity of free Dox and Apt-DoxLip, suggesting that all the Dox loaded in Apt-Dox-Lip was eventually released and available to the cancer cells. Although the AS1411 aptamer itself has been reported to be cytotoxic towards MCF-7 cells, 40 the amount of aptamer used here was much less than that necessary to cause signicant cell death.
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The cell viability was mainly determined by the amount of Dox delivered into the MCF-7 cells. Therefore, Apt-Dox-Lip can strongly bind to and be internalized by MCF-7 cells, leading to selective delivery of the encapsulated anticancer drug into cells and improved antiproliferative activity in cancer cells in vitro.
In vivo antitumor efficacy of aptamer-functionalized liposomes
We next examined the efficacy of Apt-Dox-Lip on the inhibition of growth of MCF-7 tumors, which were established by injecting MCF-7 cells subcutaneously into athymic nude mice. Human breast cancer MCF-7 cells are hormone-dependent cells, requiring estrogen to maintain the growth of primary tumors in mice. 42, 43 Therefore, the engrament and growth of MCF-7 tumors was supported by estrogen pellets subcutaneously implanted in the interscapular region of mice prior to cell injection. Nude mice were treated with Apt-Dox-Lip or Ctrl-DoxLip (25 mg Dox equivalent per tumor) every 4 days. Tumors were measured every 4 days, and the tumor growth curves are displayed in Fig. 5a . Tumors in the E2 group maintained a high growth rate in the presence of exogenous estrogen released by the E2 pellets, and the relative average tumor size increased to 166% at the end of the study (Day 24) compared to the tumor size at the start of treatment (Fig. 5b) . Analysis of relative tumor size using the PROC MIXED of SAS showed that the Apt-Dox-Lip signicantly inhibited MCF-7 tumor growth induced by E2 through the study duration, and was more effective than the Ctrl-Dox-Lip control group (p ¼ 0.004, Fig. 5a ). At the end of the study, the observed relative tumor size of 95% in the Apt-DoxLip group was signicantly different from the 120% observed in the Ctrl-Dox-Lip group (Fig. 5b) . Furthermore, treatment with Apt-Dox-Lip caused an earlier onset of tumor inhibition on Day 8 when compared with the onset of Day 16 in Ctrl-Dox-Lip (Table S2 †) . These results strongly suggested that Apt-Dox-Lip inhibited estrogen-induced MCF-7 tumor growth more effectively when compared with Ctrl-Dox-Lip.
To examine the toxicity of Apt-Dox-Lip to mice, the body weights of mice were monitored weekly to assess their overall health. The SAS PROC MIXED analysis of the interaction of time and treatment showed no difference between the E2, Apt-DoxLip and Ctrl-Dox-Lip groups (Fig. S7a †) , indicating that the overall health of the animals was not affected during the course of the study. The 3 experimental groups also maintained 100% survival rate throughout the study. Daily food intake was measured twice, and no signicant differences were found in food intake among the 3 experimental groups in this study (Fig. S7b †) .
Tumor penetration study of aptamer-functionalized liposomes
To investigate the possible reasons for the enhanced efficacy of Apt-Dox-Lip in suppressing MCF-7 tumor growth, we compared the tumor penetration behavior of Apt-Dox-Lip and Ctrl-Dox-Lip aer they were injected intratumorally into the MCF-7 tumors in mice. The tumors were collected 1 h post injection, sectioned and stained with DAPI (Fig. 6a) . The uorescence microscope images of the whole injection area revealed a marked increase of penetration depth into surrounding tumor tissues by AptDox-Lip as compared to Ctrl-Dox-Lip (doxorubicin uorescence shown in red). The uorescence intensity plot prole was analyzed by ImageJ, as shown in Fig. S8 . † The center of peak correlates to the initial injection site and the half width of the peak is an estimate of the penetration radius from the injection site to the surrounding tissues. Tumor sections treated with Apt-Dox-Lip showed not only overall enhanced uorescence intensity (y axis of Fig. S8 †) , but also a larger area with uo-rescence (x axis of Fig. S8 †) . Apt-Dox-Lip penetrated up to $1000 mm from the injection site at 1 h post injection while Ctrl-DoxLip exhibited much smaller penetration depth ($500 mm).
The passive diffusion of the liposomes into tumors was also evaluated in an ex vivo experiment to compare their penetration in tumor tissues mimicking the situation of a intratumoral injection of liposomes. MCF-7 tumors collected from athymic nude mice were incubated with Apt-Urn-Lip or Ctrl-Urn-Lip in cell medium for 24 h. The tumors were then collected, sectioned, stained with DAPI and imaged via confocal microscope. The results shown in Fig. S9 † suggest that Apt-Urn-Lip was taken up more in tumor tissues than Ctrl-Urn-Lip (uranin shown in green uorescence). Together, these results demonstrated that Apt-Dox-Lip could better penetrate MCF-7 tumor tissue due to the targeting effect of surface bound NCL-Apt, thus facilitating the efficient delivery of anticancer drugs more deeply into tumor tissues than Ctrl-Urn-Lip. This could be one of the reasons that Apt-Urn-Lip showed improved efficacy against MCF-7 tumors.
To further determine whether the liposomes were actually internalized by cancer cells inside tumor tissue or simply stayed in the interstitial space of tumor tissues, the MCF-7 cells in the tumor tissue sections were analyzed with confocal uorescence microscopy (Fig. 6b) . Much more red uorescence was observed inside MCF-7 cells in the tissue sections from the mice treated with Apt-Dox-Lip than Ctrl-Dox-Lip, suggesting that the targeted liposomes also enhanced cellular internalization in vivo. This result agreed well with the observed enhancement in internalization by MCF-7 cells in vitro as demonstrated above.
Apt-Dox-Lip is shown to be taken up by MCF-7 cells efficiently, resulting in more efficient delivery of the anticancer drug doxorubicin to cancer cells in vivo, thus leading to more efficient killing of cancer cells. These results are comparable with previous reports using anti-HER2 antibody 44 and 
Conclusions
In conclusion, we have demonstrated the successful formulation of doxorubicin-encapsulated, AS1411 aptamer-functionalized liposomes as a drug delivery system that was able to target nucleolin. In vitro studies showed the high targeting efficiency of AS1411 aptamer-functionalized liposomes toward MCF-7 cells with overexpressed nucleolin. Enhanced cytotoxicity and antitumor efficacy were observed in MCF-7 cells and in MCF-tumor bearing mice with the use of AS1411 aptamer-functionalized liposomes versus control liposomes. Aptamer-functionalized liposomes exhibited enhanced tumor penetration ability, which could account for the improved antitumor efficacy observed in vivo. In conjunction with the high stability and excellent biocompatibility of liposomes, the AS1411 aptamer-functionalized liposome demonstrated here shows excellent potential as a new modality for targeted cancer therapy.
Materials and methods

Chemicals and materials
Chemicals and reagents used in this study were obtained from Sigma-Aldrich Inc. (St. Louis, MO) and used as received. HSPC, cholesterol, mPEG2000-DSPE, and extruder were obtained from Avanti Polar Lipids, Inc (Alabaster, AL). Sephadex G-100 medium was purchased from GE Healthcare (Chalfont St. Giles, UK). OliGreenÒ ssDNA reagent was obtained from Invitrogen (Carlsbad, CA). All oligonucleotides used in this study were purchased from Integrated DNA Technologies Inc. 
Formulation of liposomes
DNA-functionalized liposomes containing either uranin (Urn) or doxorubicin (Dox) were formulated from hydrogenated soy phosphatidylcholine (HSPC), cholesterol, and distearoyl phosphatidyl-ethanolamine modied with methoxy poly(ethylene glycol) with a molecular weight (MW) of 2000 Da (mPEG2000-DSPE) (see ESI †).
Determination of DNA concentration, density and conjugation efficiency
The OliGreenÒ ssDNA reagent (Invitrogen, USA) was utilized to measure the concentration of DNA strands. DNA-modied liposome samples were treated with Triton-X and heated at 80 C for 20 minutes to rupture liposomes and release DNA strands prior to the staining process. A standard curve was obtained from a series of standard DNA solutions following manufacturer's instructions (see ESI †).
In vitro cellular internalization and cytotoxicity studies MCF-7 cells were seeded, washed, and incubated with Opti-MEM containing either Apt-Urn-Lip or Ctrl-Urn-Lip (50 mM lipid equivalent) samples. The cells were stained, xed, and then subsequently imaged on a confocal laser scanning microscope (LSM700, Carl Zeiss, NY). Cells without the addition of Urn-Lip were imaged as control. Both the percentage of the uorescent cells relative to the total analyzed cells and the uorescence intensity of the uorescence-positive cells were assessed. Fresh medium containing Dox, Ctrl-Dox-Lip, or Apt-Dox-Lip in concentrations ranging from 10 nM to 500 nM of Dox or equivalent Dox was used for cytotoxicity study. Cell viability was determined by the MTT assay (see ESI Section S3 †). Standard MTT assay protocols were followed thereaer.
Animals
Female athymic nude mice were purchased from Charles River (Wilmington, MA) and ovariectomized at the age of 21 days by the vendor. Aer arrival, mice were single-cage housed, with free access to food and water. Articial light was provided in a 12/12 hour cycle. The AIN-93G semi-puried diet (Dyets, Bethlehem, PA) was selected as it has been established to meet the nutritional requirements of mice.
47 Animals were maintained under animal protocols approved by the Institutional of Animal Care and Use and Committee at the University of Illinois at Urbana-Champaign.
Efficacy study using MCF-7 xenogras A 1 mg estrogen pellet (1 mg : 19 mg estrogen : cholesterol) was subcutaneously implanted into the intrascapular region on each mouse. Four days aer pellet implantation, human breast cancer MCF-7 cells were suspended in MatrigelÔ and subcutaneously injected into four sites (2 Â 10 5 cells per site) on the ank of each mouse. Tumors were measured with a caliper every four days, and the tumor cross sectional area was calculated using the formula (length/2) Â (width/2) Â 3.14.
48 When the average tumor cross sectional area reached 40 mm 2 , the animals were normalized by their tumor size and distributed into 3 groups: estrogen (E2) group (animal n ¼ 4, tumor n ¼ 11), Apt-Dox-Lip group (animal n ¼ 5, tumor n ¼ 21), Ctrl-Dox-Lip group (animal n ¼ 6, tumor n ¼ 22), and the treatment was initiated. Apt-Dox-Lip or Ctrl-Dox-Lip (25 mg Dox equivalent) was directly injected into each tumor every 4 days for 24 days. The mice in the estrogen group received the same volume of PBS per tumor. The cross sectional area of each tumor was calculated at each time point, and expressed as a percentage of the tumor area at the onset of treatment (100%), as described previously. Daily food intake was measured twice, the rst time 3 weeks post cell injection (measurement 1, M1) and the second time 3
weeks post treatment initiation (M2). Body weight was monitored weekly.
Ex vivo tumor penetration study
Female athymic nude mice bearing MCF-7 tumors were sacriced to collect the tumors when the average tumor size reached $4.0 Â 4.0 mm. Whole tumors (n ¼ 3) were ex vivo cultured with Ctrl-Urn-Lip or Apt-Urn-Lip at concentration of 10 mg equivalent uranin per mL in cell medium for 24 h. Tumors without any treatment served as the control. Tumor sections (5 mm) were collected by cryostat, mounted on glass slides, and imaged.
In vivo tumor penetration study
Female athymic nude mice bearing MCF-7 tumors were divided randomly into groups of three (n ¼ 3) and were treated when the average tumor size reached 5.0-6.0 mm. Animals in each group received a PBS solution, Ctrl-Dox-Lip, or Apt-Dox-Lip (25 mL, 1 mg doxorubicin equivalent per mL) respectively through intratumoral injection. The animals were euthanized 1 h aer administration, and tumor sections (10 mm) were collected by cryostat, mounted on glass slides, and imaged.
Statistics
All statistical data analysis was conducted using either SASÔ 9.2 (SAS Institute Inc., Cary, NC) or OriginProÒ 8.5 (OriginLab Corporation, Northampton, MA) program. Data of food intake and tumor size measured on the same time point were analyzed using one-way ANOVA (OriginPro) with post hoc Fisher's LSD test. Continuous data of body weight or tumor size over the duration of the study were analyzed using the PROCEDURE MIXED of SAS. P < 0.05 was considered signicantly different between treatment groups.
